¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö : 2024-02-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö : 2024-02-17
±³À°ÀÏÀÚ : 2024-02-17
±³À°Àå¼Ò : aT¼¾ÅÍ 4Ãþ âÁ¶·ë

±³À°ÁÖÁ¦ : 2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : À¯ÁöÀÎ
¿¬¶ôó : 02-714-9071  

À̸ÞÀÏ : diabetes@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 20,000¿ø  

ºñ°í "»çÀüµî·Ï 10,000¿ø

ÇöÀåµî·Ï 20,000¿ø"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:00~13:15 Understanding the Pathogenesis of Atherosclerosis by Dissecting Gene Expression Profile at the Single Cell Level ÃÖÀçÈÆ(ÇѾç´ë »ý¸í°úÇаú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:15~13:30 Phenotypic Plasticity of Vascular Smooth Muscle Cells in Aortic Aneurysm: Role of Mitochondria Çã°æ¼±(Ãæ³²´ë ¾àÇаú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:30~13:45 Tetrahydrobiopterin is a Promising Target of Diabetic Cardiomyopathy via Restoring Mitochondria Function ±èÇü±Ô(ÀÎÁ¦ÀÇ´ë ½ÉÇ÷°ü¹× ´ë»çÁúȯ¼¾ÅÍ)

Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:45~14:00 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¹Ú¿ë½Ä(°æÈñÀÇ´ë ¹Ì»ý¹°Çб³½Ç)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:00~14:15 Lower is Better: Optimal LDL Targets for Diabetic Patients at 55 mg/dL or 70 mg/dL? ·ùÇýÁø(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:15~14:30 The Role of Rivaroxaban: What You Need to Know in Diabetes ÀÌ°æ¾Ö(ÀüºÏÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:30~14:45 SGLT2 inhibitor and GLP1-RA: Standouts as Cardioprotective Agents ¹ÚÁøÁÖ(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:45~15:00 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ±è¹Ì°æ(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)

ÈÞ½Ä 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:00~15:20 ÈÞ½Ä ( )

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:20~15:35 Vascular Factors in Diabetic Neuropathy ±èÁ¾È­(ºÎõ¼¼Á¾º´¿ø ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:35~15:50 Diabetic Nephropathy and Endothelial Dysfunction ÀüÀçÇÑ(°æºÏÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:50~16:05 Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Retinopathy ¾çÁö¸í(µ¿±¹ÀÇ´ë ¾È°ú)

Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:05~16:20 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¿øÁ¾Ã¶(ÀÎÁ¦ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:20~16:35 Is It Time to Reclassify Diabetes Complications? Assessing the Adequacy of Microvascular and Macrovascular Classification ±èÁøÈ­(Á¶¼±ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:35~16:50 Do Type 1 and Type 2 Diabetes have the Same Vascular Complications? Á¶À±°æ(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø ³»ºÐºñ³»°ú)

±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:50~17:05 Diabetes Duration: Is It an Important Factor in the Occurrence of Vascular Complications? ¹èÀçÇö(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 17:05~17:20 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¼­¹ÌÇý(¼øõÇâÀÇ´ë ³»ºÐºñ³»°ú)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö : 2024-02-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2024³â ´ëÇѺ´¸®ÇÐȸ ºÐÀÚº´¸®±³À° : 2024-02-17
´ÙÀ½±Û ´ëÇÑÃéÀå´ãµµÇÐȸ È£³²Áöȸ Á¦27ȸ Ãá°èÇмúÁý´ãȸ : 2024-02-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20835 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ 2024³â Á¦ 1ȸ ³»½Ã°æ Áý´ãȸ : 2024-06-21 0 8 2024-05-27
20834 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¾È°ú ±Ý¿äÁý´ãȸ : 2024-06-21 0 2 2024-05-27
20833 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 1ÀÏÂ÷ : 2024-06-21 0 4 2024-05-27
20832 ¼­¿ï Á¦8Â÷ µµºÀ±¸ÀÇ»çȸ Çмú¼¼¹Ì³ª(½ÉÇ÷°üÁúȯ ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á, ºÒ¸éÁõ, Ä¡¸Å¾à¹°Ä¡·á, Ç×Ç÷ÀüÁ¦) : 2024-06-21 0 2 2024-05-27
20831 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (2ÀÏÂ÷) : 2024-06-21 0 3 2024-05-27
20830 Á¦ÁÖ ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-21 0 1 2024-05-27
20829 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(1ÀÏÂ÷) : 2024-06-20 0 2 2024-05-27
20828 ºÎ»ê ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2024-06-20 0 8 2024-05-27
20827 ºÎ»ê ´ëÇѾȰúÇÐȸ ºÎ»êÁöȸ Á¦ 510ȸ ÇмúÁý´ãȸ : 2024-06-20 0 2 2024-05-27
20826 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (1ÀÏÂ÷) : 2024-06-20 0 2 2024-05-27
20825 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÅëÁõÇÐȸ ¼­¿ïÁöȸ Áý´ãȸ : 2024-06-20 0 3 2024-05-27
20824 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À°(¼­½Ä ÀÛ¼º ½ÇÁ¦) : 2024-06-20 0 1 2024-05-27
20823 °æ±â µ¿±¹´ëÇб³ Àϻ꺴¿ø : °ñ°üÀý¿°ÀÇ Áø´Ü ¹× Ä¡·á : 2024-06-19 0 6 2024-05-27
20822 °æ±â ´ëÇÑ°£ÇÐȸ Overlooked Liver Diseases : 2024-06-19 0 9 2024-05-27
20821 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦2ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-06-17 0 14 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷